Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28328163 | 0.88 | PAM (0.52) | ALDH1A1PAMDGKAMAPTMEN1 | |
| SCHEMBL27573979 | 0.85 | PAM (0.62) | ALDH1A1PAMDGKAMAPTMEN1 | |
| SCHEMBL10446 | 0.84 | ALDH1A1 (0.55) | ALDH1A1DGKAHDAC3HDAC1HDAC2 | |
| SCHEMBL27697176 | 0.83 | NAAA (0.39) | ALDH1A1PAMMEN1POLBKMT2A | |
| SCHEMBL11765115 | 0.82 | ALDH1A1 (0.52) | ALDH1A1DGKAHDAC3HDAC1HDAC2 | |
| Water SCHEMBL28271653 | 0.82 | ALDH1A1 (0.52) | ALDH1A1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28813361 | 0.82 | ALDH1A1 (0.52) | ALDH1A1HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL28392661 | 0.82 | ALDH1A1 (0.52) | ALDH1A1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL179682 | 0.82 | CYP1A2 (0.39) | PAMMEN1KMT2AL3MBTL1HDAC3 | |
| SCHEMBL20872192 | 0.82 | HDAC3 (0.33) | ALDH1A1PAMMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328919-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140286873-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | CERULEAN PHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130202659-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130011445-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CRAWFORD THOMAS C (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120282306-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110268658-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110262490-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | CERULEAN PHARMA INC (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885PAM 2818/4885DGKA 1012/4885 |
| US-20130202659-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885PAM 2818/4885DGKA 1012/4885 |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885PAM 2818/4885DGKA 1012/4885 |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885PAM 2818/4885DGKA 1012/4885 |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885PAM 2818/4885DGKA 1012/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885PAM 2818/4885DGKA 1012/4885 |
| US-20110268658-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
| US-20130011445-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
| US-20140286873-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
| US-20110262490-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | ALDH1A1 3058/4885PAM 2884/4885DGKA 2165/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | ALDH1A1 3058/4885PAM 2884/4885DGKA 2165/4885 |
| US-20140328919-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
| US-20120282306-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | LPXN, LIPA, CHMP4B | ALDH1A1 3868/4885PAM 1673/4885DGKA 2514/4885 |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885PAM 186/4885DGKA 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.